Yantai Dongcheng Pharmaceutical Group (002675) Stock Overview

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C. The company also provides nadroparin calcium, hydrocortisone sodium succinate, chorionic gonadotrophin, and menotropins for injection, as well as ambroxol hydrochloride dispersible tablets, jinjunling capsule, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind dispelling itch relieving granule. In addition, it offers Technetium [99Tc] Methylene Diphosphonate Injection; Technetium [99mTc] Tc labeled tracers; 2-[18F]FDG that helps to detect the activity of tumor cells; sodium iodide [131I] oral solution; iodine [125I] seed use to treat internal radiation of various malignant tumors; [14C]Urea capsule; and jiabaolin glucosamine chondroitin sulfate capsule. The company also exports its products to approximately 40 countries and regions, including the Europe, America, Asia Pacific, and internationally. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is based in Yantai, China.